Clinical investigations of plasma homovanillic acid concentrations
Several lines of evidence suggest that abnormalities of central dopaminergic transmission may be involved in the expression of some schizophrenic symptoms. However, elucidation of the role of dopamine (DA) in schizophrenia has eluded investigative efforts. Presently, no accurate and easily repeatable measure of brain DA activity exists. Measurements of CSF homovanillic acid concentrations and determination of growth hormone and prolactin plasma levels, whose secretion is under central dopaminergic control, has major limitations. A more promising technique, positron emission tomography, is not yet available for routine research use.
KeywordsSchizophrenic Patient Cortical Atrophy Homovanillic Acid Schizophrenic Symptom Chronic Schizophrenic Patient
Unable to display preview. Download preview PDF.
- 6.Davila R, Zumarrage M, Perea K, Andia I, Friedhoff AJ (1987). Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment. Arch Gen Pscyh 44: 837–838Google Scholar
- 8.Wolkowitz OM, Breier A, Doran A, Kelose J, Lucas P, Paul SM, Pickar D (1986). Aprazolam Augmentation of Neuroleptic Antipsychotic Effects. Presented at the American College of Neuropsychopharmacology, Washington, DCGoogle Scholar
- 10.Weinberger DR (1987). Implication for normal brain development for the pathogenesis of schizophrenia. Arch Gen Psych, 44: 660–669Google Scholar
- 12.Kendler KS, Mohs RC, Davis KL. The effects of diet and physical activity on plasma homovanillic acid in normal human subjects. Psychiatr Res, 8: 215–223Google Scholar
- 14.Karoum F, Karson CN, Bigelow LB, Lawson WB, Wyatt RJ (1987). Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psych, 44: 604–607Google Scholar
- 15.Pickar D, Labarca R, Doran A, Wolkowitz GM, Roy A, Breier A, Linnoila M, Paul SM (1986). Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psych 43: 669–676Google Scholar
- 16.Keefe RSE, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL (1987). Characteristics of very poor outcome schizophrenia. Am J Psych, 144: 889–895Google Scholar
- 18.Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA, Young TK, Malat J, Williams JA, O’Tauma LA, Snyder SH, Kuhar MJ, Gjedde A (1986). Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Sci, 234: 1558–1563CrossRefGoogle Scholar
- 20.Bannon MJ, Reinhard JF, Jr., Bunney EF, Roth RH (1982). Unique response to antipsychotic drugs is due to absence of terminal receptors in mesocortical dopamine neurons Nat, 296: 444–446Google Scholar
- 21.Weinberger DR, Berman KF, Zec RF (1986). Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: regional cerebral blood flow (rCBF) evidence. Arch Gen Psych, 43: 114–125Google Scholar
- 22.Berman KF, Zec RF, Weinberger DR (1986). Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. Role of medication, attention and mental effort. Arch Gen Psych, 43: 114–125Google Scholar